Slides
Page 1
2026 Annual General Meeting Thursday, 22 October 2026 Swissotel, Sydney
Page 2
Forward-looking statements This presentation may contain forward-looking statements regarding Healius Limited’s financial performance, guidance and business prospects. These statements are subject to risks and uncertainties, many beyond the company’s control and are based on management’s current expectations and estimates as at the date made. Actual results may differ materially due to factors including but not limited to regulatory changes, unfavourable decisions by Governments, healthcare / other regulators, competitive and billing changes, litigation, loss of contracts or cost increases. Past performance also cannot be relied upon as a guide to future performance. The presentation does not constitute an offer to sell, or solicitation to buy or sell any securities of Healius Limited. No representation, warranty or assurance is given as to the accuracy or achievement of any forward-looking statement, and given these uncertainties, readers should not place undue reliance on them including when making investment decisions. Except as required by law, Healius Limited does not undertake to update forward-looking statements whether because of new information or future events. Healius Limited 2026 Annual General Meeting2
Page 3
CEO Presentation Paul Anderson Healius Managing Director & Chief Executive Officer
Page 4
Pathology is the quiet engine of evidence-based care 4 Healius Limited 2026 Annual General Meeting Pathology enables early diagnosis and timely intervention 70% of medical treatment decisions and 100% of cancer diagnoses rely on pathology Pathology data can provide unparalleled insights into the nation’s health
Page 5
T27 Scorecard – Performance Update FY26 5 Delivery complete Partially delivered On track>✓ ▸Our aim is to deliver mid-to-high single-digit EBIT margins by December 2028 People & Ways of Working Digital Technologies Emerging Diagnostics Laboratory Modernisation Customer Service • Collections: >80% of ACC episodes now processed through Medway Collections • Enhanced CX: 220k patient appointments booked (new capability from Aug 25) • Core growth: ~1,500 new referrers added in 2H26 • Collections: New HubSpot CRM capability implemented to improve service for referrers • Enhanced CX: FY26 Contact Centre response times improved 1.9x vs pcp • Core growth: FY26 average fee growth of 4.0% over FY25 • Lab: Regional lab optimisation with 24.3% reduction in FTEs vs FY25 • Lab: Productivity gain from main lab optimisation with 1.6% less FTEs vs 4Q25 • Consumables spend: 15.3% as % of revenue vs pcp of 16.2% • Genomics: Revenue up 16.9% in FY26 vs pcp • Vetnostics: Digital courier, consumables ordering in place (100% take-up), full digital solution in build • B2B: Full year benefit from new commercial contracts • Medway: New Diabetes Audit functionality in market with ~1k referrers onboarded • Medway: eReferral growth continues – FY26 volumes 39.7% higher vs pcp • Digital AP: Majority of inter-state AP work digitised, new scanners fully embedded • Corporate costs: Total of $24.4m (annualised) cost savings delivered • New National Collector Training Academy operational: 600+ collectors graduated • FY26 labour costs: Flat on FY25 despite FWC decision, now 49.7% (as % of revenue) • AI workers: Reva AI and Melinda AI – working on high volume finance transactions • AI workers: Julie AI and Oscar AI – working on workforce planning • AI workers: Additional digital co-workers being developed in priority operational areas ▸ ✓ ✓ ▸ ✓ ▸ ▸ ▸ ▸ • Lab: Laverty Microbiology automation setup, validation in progress • Lab: Pathway LIS being implemented across all disciplines • Logistics: 100% of metro courier runs digitised, 33% reduction overtime vs pcp ▸ ▸ • Genomics: 15 new products launched in FY26, focus on hereditary cancer detection • Vetnostics: FY26 revenues up 3.4% over pcp • B2B: Clinical Trials FY26 revenue up 92.9% vs pcp ▸ ▸ ✓ ▸ • Medway: New Patient App in “soft-live” across internal users, go live in 1H27 • Pathway: High volume Genetics workflows (Reproductive & Oncology) built & in roll out • Digital AP: IBEX AI enabled cancer detection extended to new tissue types ▸ ▸ ▸ ✓ ▸ ▸ ▸ ▸ ✓ ✓ ▸ >✓ Healius Limited 2026 Annual General Meeting ✓ ✓ ▸
Page 6
The role of pathology in prevention 6 Health Misinformation Research Update February 2026 Diabetes Watch Report November 2025 Women & Cardiovascular Disease in Australia September 2026 We believe we have a broader role to play in supporting better health outcomes for Australians through information and awareness Healius Limited 2026 Annual General Meeting